GSK plc vs Axsome Therapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: GSK plc vs Axsome Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, GSK plc and Axsome Therapeutics, Inc. have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, GSK's SG&A expenses have remained relatively stable, fluctuating around the $9 billion mark, with a peak in 2019. This consistency reflects GSK's established market presence and strategic cost management.

Conversely, Axsome Therapeutics has shown a dramatic increase in SG&A expenses, skyrocketing from a modest $1.4 million in 2014 to over $320 million in 2023. This 22,900% surge underscores Axsome's aggressive expansion and investment in market penetration. As Axsome continues to grow, its SG&A expenses highlight its commitment to scaling operations and enhancing its competitive edge. These trends offer valuable insights into the financial dynamics and strategic priorities of these pharmaceutical giants.